对轻度至中度帕金森病进行结肠镜便微生物移植:随机对照试验
Jingyi Wang1, Liujun Xue2, Minna Zhang1
1Department of Gastroenterology, the Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian 223301, China.
Brain, behavior, and immunity
|August 23, 2025
概括
通过结肠镜进行新鲜便微生物移植 (FMT) 有效治疗帕金森病 (PD) 的症状. 这种安全的程序可以改善运动和非运动功能,便秘和生活质量至少12周.
科学领域:
- 胃肠病学和神经病学
- 微生物组研究
- 临床试验
背景情况:
- 帕金森病是一种神经退行性疾病,治疗选择有限.
- 便微生物种移植 (FMT) 对PD有希望,但传递方法和微生物种活力令人担忧.
- 结微生物群可以减少多样性和有效性,强调需要新的FMT方法.
研究的目的:
- 通过结肠镜对轻度至中度PD患者进行新鲜FMT的疗效和安全性评估.
- 评估新鲜FMT对运动和非运动症状,便秘,生活质量,认知,情绪和睡眠的影响.
- 在新鲜的FMT后探索肠道微生物群和便代谢物的变化.
主要方法:
- 一个单中心,双盲,随机,安慰剂对照试验,涉及30名轻度至中度PD患者 (Hoehn-Yahr阶段I-III).
- 参与者被随机分为1:1接受通过结肠镜检查的新鲜FMT或通过结肠镜检查的盐溶液安慰剂.
- 在基线和治疗后4,8和12周进行了对PD症状,生活质量和其他相关参数的全面评估.
主要成果:
- 在12周后,新的FMT显著改善了UPDRS III,PAC- QOL,UPDRS II,NMSS,PDQ-39,HAMA和HAMD等级的得分.
- 用每周CSBM和布里斯托尔便尺度测量便秘,在FMT组显著改善.
- 甲基因组和代谢组分析显示肠道微生物群和便代谢物的显著变化,没有报告的不良事件.
结论:
- 通过结肠镜进行新鲜的FMT是一种对轻度至中度PD的安全且耐受良好的治疗方法.
- 这一程序有效地缓解了运动和非运动症状,改善了肠道功能,提高了生活质量.
- 观察到的益处持续至少12周,可能与肠道微生物群和便代谢物的恢复有关.
相关概念视频
01:24Parkinson's Disease: Treatment
377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
01:21Drugs for Treatment of Constipation-Predominant IBS
331
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
331
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
01:15Parkinson's Disease: Overview
703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703